Search PubMed⌕ Search

Biomedical subjects

J Brasseur

Publications and source records attributed to J Brasseur.

8 recordsLinked to original sources
PubMed1993

Clinical supervision.

Explore the source record for details and available documents.

American Speech-Language-Hearing Association↗
PubMed1989

Performance of university students on the Fullerton subtest of idioms.

The study examined the performance of 71 university students on the Fullerton Language Test for Adolescents subtest on Idioms. The subjects were assigned to one of three age categories, and the performances of the groups were compared. The results demonstrated that 51% of the 18-21-year-old group fell within the "Competence Range" for this subtest, while 84% of the 22-29-year-old group and 91% of the 30+ year-old group fell within this range. As chronological age increased, performance improved.

Adolescent↗
PubMed1989

Indirect clinical evidence that 1 alpha OH vitamin D3 increases the intestinal absorption of aluminum.

In a previous study we showed that 1 alpha OH vitamin D3 [1 alpha (OH)3] given to 16 hemodialyzed patients taking Al(OH)3 at a constant dose increased their plasma concentrations of aluminum [Demontis et al. 1986]. In order to choose between 2 possible mechanisms explaining this increase (increased intestinal absorption or decreased tissue storage of aluminum), we gave, in the present study, 1 alpha (OH)3 the same dose (6 micrograms per week) for the same period (4 weeks) to 15 stable hemodialyzed patients after their Al(OH)3 had been discontinued for 6 weeks. Under Al(OH)3 treatment they had a mean plasma aluminum (2.33 +/- 2.36 mumol/l) which was not significantly different from that of the patients in our former study (1.23 +/- 0.25 mumol/l). After Al(OH)3 discontinuation, plasma aluminum (measured by inductively coupled plasma emission spectrometry) decreased significantly as early as the 2nd week of the control period (1.39 mumol/l). The decrease was maintained at a plateau throughout the 5 weeks of the control period (1.38 mumol/l), the 4 weeks of 1 alpha OH vitamin (vit) D3 administration (1.40 mumol/l) and the 8 weeks of the post 1 alpha (OH)3 period (1.22 mumol/l). Plasma calcium and phosphate concentrations increased significantly with 1 alpha (OH)3 and decreased thereafter whereas plasma PTH concentrations decreased during 1 alpha (OH)2 D3 and increased after its discontinuation suggesting biological activity of 1 alpha (OH)3. Since 1 alpha (OH)3 increases plasma aluminum in hemodialyzed patients only when they are simultaneously taking Al(OH)3, it is suggested that this increase is explained by an increase of intestinal absorption of aluminum and not by a tissue redistribution of aluminum.

Adolescent↗
PubMed1988

[Indirect evaluation of the effect of 1 alpha-hydroxyvitamin D3 on intestinal absorption of aluminum].

In a former study we have shown that 1 alpha OH vitamin D3 given to hemodialyzed patients taking A1(OH)3 at a constant dose increased their plasma concentrations of aluminium. Two mechanisms can explain this increase: increased intestinal absorption or decreased tissue storage of aluminium. We have, in the present study, given 1 alpha(OH)3 at the same dose (6 micrograms per week) and during the same duration (4 weeks) to 15 stable hemodialyzed patients after aluminium hydroxide has been discontinued 6 weeks before. Under A1(OH)3 treatment mean plasma aluminium was 2.33 +/- 2.36 mumol/l. After A1(OH)3 discontinuation, plasma aluminium decreased significantly as soon as the 2nd week of the control period (1.39 mumol/l). The decrease was maintained in plateau throughout the 5 weeks of the control period (1.38 mumol/l and, the 4 weeks of 1 OH Vit D3 administration (1.40 mumol/l). After 1 alpha OH D3 discontinuation there has been a non significant transient drop of aluminemia followed by a plateau at a level comparable to the previous plateau. Plasma calcium and phosphate concentrations increased significantly with 1 alpha(OH)3 and decreased thereafter confirming biological activity of 1 alpha(OH)3. Since 1 alpha(OH)3 increases plasma aluminium in hemodialyzed patients only when they are taking simultaneously A1(OH)3, it is suggested that this increase is mainly explained by an increase of the intestinal absorption of aluminium.

Adult↗